Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Winfastorlose who wrote (9691)	5/6/2020 1:26:34 PM
From: benwood	1 Recommendation Recommended By Winfastorlose Respond to of 26463

I assume this was put on the list to keep Twitter from collapsing? -g- — Crabbing

To: Winfastorlose who wrote (9691)	5/8/2020 8:37:55 PM
From: Kirk ©	Read Replies (1) \| Respond to of 26463

Well, if it was/is a conspiracy to have Trump fail due to the economy... they need a new leader. I heard some whining on the news a few minutes ago that CA unemployment would be much worse if they counted the illegal aliens who didn't get work... of course they used a different term. Also, all those construction and gardening jobs stopped but are back working this week so they would make the rate BETTER than reported. Add in the illegals supposedly picking our produce, that haven't stopped working, and it is even better yet... but that doesn't fit the MSM narrative.

To: Winfastorlose who wrote (9691)	5/11/2020 12:07:42 AM
From: Kirk ©	1 Recommendation Recommended By Winfastorlose Respond to of 26463

Here is an insightful piece from a surprising source: Formerly One of the most powerful Democrats in California (in his younger days after he "retired and became mayor of SF where he was) Kamela Harris's former married lover who gave her her start to power with one of those commission jobs that makes me wonder if they do anything but collect State reward money.... This can’t go on. California has to figure a way out Willie Brown May 9, 2020 Updated: May 9, 2020 4 a.m. sfchronicle.com And trying to keep businesses from opening with threats of suspending their liquor licenses or cosmetologist licenses won’t work — not on a mass scale that would be needed if many people start to say: enough. The goal of the shutdown was to curb the coronavirus and keep the hospitals from being swamped. We kept the hospitals working, but we have yet to curb the virus and a vaccine is probably at least a year away. In the meantime, we’re headed over the economic cliff and facing unemployment numbers the likes of which we have never seen before. I think more "choice" is coming...

To: Winfastorlose who wrote (9691)	5/15/2020 12:18:02 PM
From: Kirk ©	1 Recommendation Recommended By Winfastorlose Read Replies (1) \| Respond to of 26463

Good news! kirklindstrom.com STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies investors.sorrentotherapeutics.com May 15, 2020 at 11:00 AM EDT STI-1499 Antibody has demonstrated in preclinical experiments (full results will be submitted to a peer-reviewed publication shortly): - 100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation - Specific binding to S1 subunit of the SARS-CoV-2 Spike protein and complete blockade of its interaction with ACE2 receptor SAN DIEGO, May 15, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration. As recently announced, Sorrento aims to generate an antibody cocktail product that would act as a "protective shield" against SARS-CoV-2 coronavirus infection and remain effective even if virus mutations render a single antibody therapy less effective over time. Sorrento has been diligently screening billions of antibodies in its proprietary G-MAB™ fully human antibody library and has so far identified hundreds of antibody candidates that bind the S1 subunit of the SARS-CoV-2 Spike protein. Approximately one dozen of these antibodies have demonstrated the ability to block the S1 protein's interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells. These blocking antibodies were further tested for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates that was previously announced on March 31, 2020 ( Sorrento Therapeutics). Among the antibodies showing neutralizing activity, one antibody stood out for its ability to completely block SARS-CoV-2 infection of healthy cells in the experiments. STI-1499 completely neutralized the virus infectivity at a very low antibody dose, making it a prime candidate for further testing and development. Initial biochemical and biophysical analyses also indicate STI-1499 is a potentially strong antibody drug candidate. Sorrento has determined STI-1499 will likely be the first antibody in the antibody cocktail (COVI-SHIELD™) it is developing, as recently announced. STI-1499 is also expected to be developed as a stand-alone therapy, (COVI-GUARD™) because of the high potency it has exhibited in experiments to date. Sorrento plans to request priority evaluation and accelerated review from regulators to determine the best pathway to make any potential treatment available as soon as possible. Sorrento's existing state-of-the-art cGMP antibody manufacturing facility in San Diego is expected to be able to produce up to two hundred thousand doses per month and the Company intends to produce a million doses at risk while seeking FDA approval for any STI-1499 product candidate. The Company is seeking potential government support and pharmaceutical partners to further scale up STI-1499 manufacturing capacity with a goal of potentially providing tens of millions of doses in a short period of time to meet the vast projected demand. "Our STI-1499 antibody shows exceptional therapeutic potential and could potentially save lives following receipt of necessary regulatory approvals. We at Sorrento are working day and night to complete the steps necessary to get this product candidate approved and available to the waiting public," stated Dr. Henry Ji, Chairman and CEO of Sorrento. About Sorrento Therapeutics, Inc. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir®"). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™ and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018. For more information, visit www.sorrentotherapeutics.com